United Therapeutics Corporation (NASDAQ:UTHR) is set to post its quarterly earnings results before the market opens on Wednesday, July 26th. Analysts expect United Therapeutics Corporation to post earnings of $3.65 per share for the quarter.
United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share for the quarter, beating analysts’ consensus estimates of $3.12 by $0.77. United Therapeutics Corporation had a return on equity of 34.74% and a net margin of 41.04%. The company had revenue of $370.50 million during the quarter, compared to analyst estimates of $399.59 million. During the same quarter in the previous year, the company posted $3.02 EPS. United Therapeutics Corporation’s revenue for the quarter was up .4% on a year-over-year basis. On average, analysts expect United Therapeutics Corporation to post $14.47 EPS for the current fiscal year and $11.23 EPS for the next fiscal year.
Shares of United Therapeutics Corporation (UTHR) opened at 129.98 on Monday. The company has a market cap of $5.86 billion, a price-to-earnings ratio of 9.13 and a beta of 1.52. United Therapeutics Corporation has a 1-year low of $110.72 and a 1-year high of $169.89. The stock has a 50 day moving average price of $130.42 and a 200-day moving average price of $137.36.
United Therapeutics Corporation declared that its board has approved a stock buyback program on Thursday, April 27th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the biotechnology company to buy up to 4.6% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.
In other news, Director Christopher Causey sold 590 shares of United Therapeutics Corporation stock in a transaction that occurred on Thursday, July 6th. The shares were sold at an average price of $132.61, for a total transaction of $78,239.90. Following the completion of the sale, the director now owns 3,875 shares of the company’s stock, valued at $513,863.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard Giltner sold 3,490 shares of United Therapeutics Corporation stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $131.12, for a total transaction of $457,608.80. The disclosure for this sale can be found here. Insiders have sold 23,783 shares of company stock valued at $3,049,521 in the last ninety days. Insiders own 7.80% of the company’s stock.
Several research analysts recently commented on UTHR shares. ValuEngine lowered United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 2nd. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research report on Monday, April 3rd. Cowen and Company reiterated a “hold” rating and issued a $121.00 price target on shares of United Therapeutics Corporation in a research report on Wednesday, April 26th. HC Wainwright reiterated a “hold” rating and issued a $95.00 price target on shares of United Therapeutics Corporation in a research report on Monday, April 17th. Finally, J P Morgan Chase & Co set a $125.00 price target on United Therapeutics Corporation and gave the stock a “hold” rating in a research report on Tuesday, April 11th. Five equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $134.50.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://transcriptdaily.com/2017/07/24/united-therapeutics-corporation-nasdaquthr-to-release-earnings-on-wednesday.html.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.